Dallas脂肪变指数可识别非酒精性脂肪性肝病患者
该研究基于Dallas心脏研究(2000–2009年)的737名成人数据,利用1H磁共振波谱(MRS)定量肝脏脂肪,定义NAFLD为肝脂肪≥5.5%,开发并内部验证了Dallas脂肪变指数(DSI)。DSI基于丙氨酸氨基转移酶、体重指数、年龄、性别、甘油三酯、血糖、糖尿病、高血压和 ethnicity,区分NAFLD的C统计量为0.824,优于4种风险分析工具。
要点
- DSI基于常规临床变量(ALT、BMI、年龄、性别、甘油三酯、血糖、糖尿病、高血压、 ethnicity)识别NAFLD。
- DSI在MRS定义的NAFLD中C统计量为0.824,优于4种现有工具。
- DSI需外部验证,可能用于NAFLD筛查、监测肝脂肪变进展和流行病学研究。
核心结论
- DSI能准确识别基于MRS数据定义的NAFLD患者。
- DSI需外部验证,但可能用于NAFLD筛查、监测肝脂肪变进展和流行病学研究。
研究设计与样本
- 研究基于Dallas心脏研究,一项多民族、基于人群的概率研究,纳入18–65岁成人,2000–2009年收集数据。
- 最终分析纳入737名患者,排除酒精使用超过中等量者。
- 采用二元多变量逻辑回归开发工具,并使用10折交叉验证进行内部验证。
主要发现
- DSI区分NAFLD与非NAFLD的C统计量为0.824。
- 基于净重分类改善和决策曲线分析,DSI优于4种风险分析工具。
关键数值与推荐
- NAFLD定义为肝脂肪含量≥5.5%(通过1H MRS定量)。
- DSI包含的变量:丙氨酸氨基转移酶水平、体重指数、年龄、性别、甘油三酯水平、血糖水平、糖尿病、高血压和 ethnicity。
临床怎么用
- DSI可基于常规临床变量识别NAFLD患者,可能用于NAFLD筛查项目。
- DSI可用于监测肝脂肪变进展和流行病学研究。
局限性
- DSI需要外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Tools have been developed to determine risk for nonalcoholic fatty liver disease (NAFLD) based on imaging, which does not always detect early-grade hepatic steatosis. We aimed to develop a tool to identify patients with NAFLD using 1H MR spectroscopy (MRS). METHODS: We collected data from the Dallas Heart Study-a multiethnic, population-based, probability study of adults (18-65 y) that comprised an in-home medical survey; collection of fasting blood samples; MRS images to measure cardiac mass/function, abdominal subcutaneous/visceral adiposity; and quantification of hepatic triglyceride concentration, from 2000 through 2009. NAFLD were defined as 5.5% or more liver fat and we excluded patients with more than moderate alcohol use; 737 patients were included in the final analysis. We performed binary multivariable logistic regression analysis to develop a tool to identify patients with NAFLD and evaluate interactions among variables. We performed an internal validation analysis using 10-fold cross validation. RESULTS: We developed the Dallas Steatosis Index (DSI) to identify patients with NAFLD based on level of alanine aminotransferase, body mass index, age, sex, levels of triglycerides and glucose, diabetes, hypertension, and ethnicity. The DSI discriminated between patients with vs without NAFLD with a C-statistic of 0.824. The DSI outperformed 4 risk analysis tools, based on net reclassification improvement and decision curve analysis. CONCLUSIONS: We developed an index, called the DSI, which accurately identifies patients with NAFLD based on MRS data. The DSI requires external validation, but might be used in development NAFLD screening programs, in monitoring progression of hepatic steatosis, and in epidemiology studies.
引用
- McHenry S, Park Y, Browning JD, et al. Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020. PMID: 31982611. doi:10.1016/j.cgh.2020.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。